新西兰Pharmac将从7月份起为1型糖尿病患者提供CGM和胰岛素泵资助。 New Zealand's Pharmac funds CGMs and insulin pumps for type 1 diabetes patients from July.

新西兰药品管理局（Pharmac）宣布，从7月起，将为1型糖尿病患者提供全额资助的连续血糖监测仪（CGM）和胰岛素泵，以改变他们的生活并更有效地管理血糖水平。 New Zealand's Pharmac announces from July, continuous glucose monitors (CGMs) and insulin pumps will be fully funded for type 1 diabetes patients, transforming their lives and managing glucose levels more effectively. 成本障碍以前限制了人们获得医疗服务的机会，但这笔新的资金将有助于缩小差距。 The cost barrier has previously limited access, but this new funding will help close the gap. 糖尿病服务部门还将致力于扩大其员工队伍，以最大限度地发挥该技术的优势。 Diabetes services will also work on expanding their workforce to maximize benefits of the technology. 我们将进行为期一个月的公众咨询，以收集有关融资方案的反馈。 A public consultation will be held for one month for feedback on funding options.